These firms are currently doing the best in the business, based on market capitalization at the end of Q2 2012, and Q2 2011. [© Lane Erickson - Fotolia.com]
#15. Elan
2012 Market Cap: $8.63 billion (6/30: 591.3 million shares *price $14.59)
2011 Market Cap: $6.67 billion (6/30: 586.4 million shares *price $11.37)
% Change: 29.4%
#14. UCB
2012 Market Cap: $8.77 billion (6/30: 179.1 million shares * price €39.84)
2011 Market Cap: $6.84 billion (6/30: 179.5 million shares * price €30.99)
% Change: 28.2%
#13. Forest Laboratories
2012 Market Cap: $8.87 billion (8/8: 265,693,834 shares * price $33.40)
2011 Market Cap: $9.09 billion (8/8: 274,555,930 shares * price $33.12)
% Change: -2.4%
#12. Regeneron
2012 Market Cap: $11.30 billion (7/13: 96,044,622 shares * price $117.64)
2011 Market Cap: $5.09 billion (7/15: 91,626,617 shares * price $55.59)
% Change: 122.0%
#11. Vertex Pharmaceuticals
2012 Market Cap: $10.64 billion (7/27: 215,807,482 shares * price $49.32)
2011 Market Cap: $10.79 billion (7/29: 208,087,899 shares * price $51.86)
% Change: -1.4%
#10. Alexion
2012 Market Cap: $18.85 billion (7/24: 193,059,462 shares * price $97.62)
2011 Market Cap: $10.48 billion (7/29: 184,530,093 shares * price $56.80)
% Change: 79.9%
#9. CSL
2012 Market Cap: $21.11 billion (A$20.099 billion)
2011 Market Cap: $18.33 billion (A$17.454 billion)
% Change: 15.2%
#8. Merck KGaA
2012 Market Cap: $21.16 billion (6/30: 217,388,939 shares * price €78.72)
2011 Market Cap: $20.14 billion (6/30: 217,388,939 shares * price €74.94)
% Change: 5.1%
#7. Celgene
2012 Market Cap: $28.38 billion (7/23: 431,423,976 shares * price $65.78)
2011 Market Cap: $27.52 billion (7/26: 458,805,956 shares * price $59.99)
% Change: 3.1%
#6. Baxter
2012 Market Cap: $32.27 billion (7/30: 547,231,164 shares * price $58.97)
2011 Market Cap: $33.36 billion (7/28: 568,256,444 shares * price $58.70)
% Change: -3.3%
#5. Teva Pharmaceutical Industries
2012 Market Cap: $34.23 billion (6/30: 868,000,000 shares * price $39.44)
2011 Market Cap: $42.96 billion (6/30: 891,000,000 shares * price $48.22)
% Change: -20.3%
#4. Biogen Idec
2012 Market Cap: $34.26 billion (7/18: 236,346,955 shares * price $144.96)
2011 Market Cap: $25.60 billion (7/22: 242,545,771 shares * price $105.56)
% Change: 33.8%
#3. Gilead Sciences
2012 Market Cap: $40.16 billion (7/20: 756,568,507 shares * price $53.08)
2011 Market Cap: $32.68 billion (7/29: 771,455,146 shares * price $42.36)
% Change: 28.5%
#2. Amgen
2012 Market Cap: $60.09 billion (7/25: 770,768,879 shares * price $77.96)
2011 Market Cap: $49.72 billion (7/27: 924,091,356 shares * price $53.80)
% Change: 20.9%
#1. Novo Nordisk
2012 Market Cap: $76.92 billion (6/30: DKK 549.1 million * price DKK 848.50)
2011 Market Cap: $60.09 billion (6/30: DKK 569.1 million * price DKK 639.50)
% Change: 28.0%
Leave a comment by clicking the “Comments” icon. We want to hear your thoughts!
NOTES:
1 Amylin Pharmaceuticals was listed ahead of Onyx Pharmaceuticals based on calculated market cap of $5.059,917,570.40, compared with $5,059,894,746.21.
2 Acquired by Bristol-Myers Squibb in a $7 billion deal completed Aug. 8.
3 Market cap figures calculated as of March 31, since outstanding shares figures were published in company’s annual report but not in Q1 results materials.
4 Dr. Reddy’s Laboratories was listed ahead of BioMarin Pharmaceuticals based on calculated market cap of $5,349,942,065.20, compared with $5,345,899,863.0831.